MEP0408A - Derivati hinociklicnog hinazolina kao inhibitori pde7 - Google Patents

Derivati hinociklicnog hinazolina kao inhibitori pde7

Info

Publication number
MEP0408A
MEP0408A MEP-04/08A MEP0408A MEP0408A ME P0408 A MEP0408 A ME P0408A ME P0408 A MEP0408 A ME P0408A ME P0408 A MEP0408 A ME P0408A
Authority
ME
Montenegro
Prior art keywords
spirocyclic
pde7 inhibitors
quinazoline derivatives
pain
compounds
Prior art date
Application number
MEP-04/08A
Other languages
Bosnian (bs)
English (en)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MEP0408A publication Critical patent/MEP0408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
MEP-04/08A 2005-12-02 2006-11-23 Derivati hinociklicnog hinazolina kao inhibitori pde7 MEP0408A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10
PCT/IB2006/003388 WO2007063391A2 (en) 2005-12-02 2006-11-23 Spirocyclic quinazoline derivatives as pde7 inhibitors

Publications (1)

Publication Number Publication Date
MEP0408A true MEP0408A (xx) 2010-02-10

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-04/08A MEP0408A (xx) 2005-12-02 2006-11-23 Derivati hinociklicnog hinazolina kao inhibitori pde7

Country Status (22)

Country Link
US (1) US7507742B2 (xx)
EP (1) EP1957467A2 (xx)
JP (1) JP2009517453A (xx)
KR (1) KR101009554B1 (xx)
AP (1) AP2008004470A0 (xx)
AR (1) AR058266A1 (xx)
AU (1) AU2006321349A1 (xx)
BR (1) BRPI0619126A2 (xx)
CA (1) CA2631535C (xx)
CR (1) CR10039A (xx)
EA (1) EA200801145A1 (xx)
EC (1) ECSP088484A (xx)
GT (1) GT200600494A (xx)
MA (1) MA30014B1 (xx)
ME (1) MEP0408A (xx)
NL (1) NL2000336C2 (xx)
NO (1) NO20082077L (xx)
PE (1) PE20071087A1 (xx)
RS (1) RS20080233A (xx)
TW (1) TW200732307A (xx)
UY (1) UY29979A1 (xx)
WO (1) WO2007063391A2 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
AP2007004161A0 (en) * 2005-04-28 2007-10-31 Pfizer Ltd Amino acid derivatives
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX2020000295A (es) * 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407604A1 (en) 2000-04-28 2001-11-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Splice variant of camp phosphodiesterase type 7 (pde7a3)
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain

Also Published As

Publication number Publication date
TW200732307A (en) 2007-09-01
MA30014B1 (fr) 2008-12-01
US7507742B2 (en) 2009-03-24
AP2008004470A0 (en) 2008-06-30
CA2631535C (en) 2010-07-27
AU2006321349A1 (en) 2007-06-07
RS20080233A (xx) 2009-07-15
EA200801145A1 (ru) 2008-10-30
ECSP088484A (es) 2008-06-30
WO2007063391A2 (en) 2007-06-07
UY29979A1 (es) 2007-06-29
GT200600494A (es) 2007-07-06
JP2009517453A (ja) 2009-04-30
KR20080059338A (ko) 2008-06-26
NL2000336C2 (nl) 2007-08-07
US20070129388A1 (en) 2007-06-07
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
AR058266A1 (es) 2008-01-30
PE20071087A1 (es) 2007-12-29
CA2631535A1 (en) 2007-06-07
NO20082077L (no) 2008-06-04
CR10039A (es) 2008-07-10
EP1957467A2 (en) 2008-08-20
BRPI0619126A2 (pt) 2011-09-13
NL2000336A1 (nl) 2007-06-05

Similar Documents

Publication Publication Date Title
MEP0408A (xx) Derivati hinociklicnog hinazolina kao inhibitori pde7
DE602004024375D1 (de) Carboxamidderivate
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200615266A (en) Organic compounds
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
SE0202539D0 (sv) Compounds
UA84712C2 (xx) N-заміщені піразоліламідилбензімідазоліли як c-kit інгібітори$n-замещенные пиразолиламидилбензимидазолилы как c-kit ингибиторы
TW200626553A (en) Novel compounds
TW200639156A (en) New compounds
SE0302192D0 (sv) Novel compounds
WO2010021934A3 (en) Azaindole inhibitors of iap
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
UA96969C2 (xx) Ациламінопіразоли як fgfr інгібітори[ациламинопиразолы как fgfr ингибиторы
EP2145878A3 (en) Aurora Kinase inhibitors
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SE0302756D0 (sv) Novel Compounds
ATE390923T1 (de) Topoisomerase-giftmittel
SE0401763D0 (sv) Compounds
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
HK1068348A1 (en) Therapeutic heterocycles as bradykinin b2 receptorantagonists
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2004044174A3 (en) Topoisomerase-targeting agents